Climb Bio (CLYM)

• Market cap: $692M
• 1 day: -0.25%
• 5 days: -6.28%
• 1 month: -7.36%
• 3 months: 36.04%
• 6 months: 170.25%
• Year to date: 222.13%
• 1 year: 694.74%
• 5 years: -24.03%
• 10 years: -24.03%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Employees: 29